

Special Issue

Liquid Biopsy in Diseases

Message from the Guest Editors

In the age of precision medicine, tumor nucleic acid characterization plays an important role in providing patients with the most appropriate diagnosis and treatment. The advancements in PCR and next-generation sequencing (NGS) paved the way for personalized medicine by enabling the genetic characteristics of tumors to be evaluated. The development of blood-based liquid biopsy technology is also at the center of the development of precision medicine. In particular, liquid biopsy has emerged as the gold standard for diagnosis and treatment following its FDA approval in 2016. We are inviting innovative and original research papers focused on the development of various technologies for cancer diagnosis and monitoring using liquid biopsy, focusing on the experimental/laboratory and pre-clinical medicine aspects. The submission of review articles describing the latest technology on this topic are also encouraged. Focusing on liquid biopsy, this Special Issue covers the use of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), circulating tumor RNA (ctRNA), miRNA, and extracellular vesicles (EV).

Guest Editors

Prof. Dr. Sehyun Shin

1. School of Mechanical Engineering, College of Engineering, Korea University, 145 Anam-ro, Anam-dong, Seongbuk-gu, Seoul 136-701, Korea

2. Nano-Biofluidnostic Engineering Research Center, Korea University, 145 Anam-ro, Anam-dong, Seongbuk-gu, Seoul 136-701, Korea

Dr. Kyong-Hwa Park

Division of Oncology/Hematology, Department of Internal Medicine, Korea University, Seoul 02841, Republic of Korea

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/109906

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).